Global needle-free diabetic care market is expected to grow at a CAGR of 7.5% during the forecast period 2017-2023.
Segmentation
The global needle-free diabetic care market is segmented on the basis of devices types into treatment devices and diagnostic devices. Treatment devices are further segmented: insulin jet injector, insulin pen, insulin inhaler, and insulin patch & pump. Diagnostic devices are also further segmented into continuous glucose monitoring and instant glucose monitoring. On the basis of treatment, the market is segmented into oral insulin, inhaled insulin, insulin patch, and others. On the basis of applications, the market is segmented into insulin delivery and others. On the basis of end users, the market is segmented into diagnostic centers, hospitals & clinics and other.
Regional Analysis
America dominates the global needle-free diabetes care market owing to large diabetic population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Europe accounts for the second largest market, which is followed by Asia Pacific. Asia Pacific is the fastest growing region in the global market due to the presence of large diabetic population.
Key Players for Global Needle-free Diabetes Care Market
Antares Pharma, Inc. (US), Bioject Medical Technologies Inc. (US), Endo International plc (US), European Pharma Group (Netherland), PharmaJet (US), Medical International Technology, Inc. (US), Valeritas, Inc. (US), PenJet Corporation (US), INJEX Pharma AG (Germany), National Medical Products Inc. (US), Crossject SA (France), Zogenix, Inc. (US), 3M Company (US).
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/needle-free-diabetes-care-market-912
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek